The phosphatases of regenerating liver (PRLs) PTPs are the most oncogenic enzymes of the PTP gene family.
These are small (Mr ~20,000) single PTP domain enzymes comprising three highly homologous members (PRL-1,-2,-3).
All PRLs are oncogenes and promote cell proliferation, tumour growth, invasion, and metastasis in over 90% of all cancers. However, the underlying molecular mechanism behind their oncogenicity remains unknown.
Kanyr has proprietary data on their mechanism of action and a proprietary small molecule lead compound inhibitor allowing for the targeting of PRLs through a newly identified co-oncogenic partner.
Kanyr identified a key PTP that negatively modulates dendritic cell activation.
We developed proprietary small molecule inhibitors against this PTP and demonstrated that these inhibitors are able to boost dendritic cell activation.
- Ex-vivo activation of APCs with proprietary PTP inhibitor for the development of therapeutic cancer vaccines
Significant advancement over current technologies